Dr. Meng Xiaofeng Appointed Co-President of Haichang Bio to Spearhead Global Expansion of Complex Injectables

May 07, 2024 11:19 CST Updated 11:19

Haichang Biotech

Innovative Formulation Developer

Recently, Haichang Biotech announced the appointment of Dr. Xiaofeng Meng as Co-President.Fully responsible for the company's production, quality, registration, and sales operations management.Dr. Meng, with his profound professional background, exceptional leadership, and global perspective, will lead Haichang Biotech to achieve more significant breakthroughs and accomplishments in the field of complex injectable internationalization.

Dr. Meng Xiaofeng has over 20 years of extensive experience in the pharmaceutical industry and is a highly acclaimed authority in international regulatory affairs and GMP compliance. He has rich experience and notable achievements in the R&D innovation of drug formulations, international registration and submission of pharmaceutical products, establishment of international standard quality systems for pharmaceutical enterprises, and market entry of drugs into Europe and the United States.

In the field of innovative drugs, Dr. Meng has successively led and participated in the registration and market launch of a new topical drug for actinic keratosis and an opioid nasal spray for cancer pain management in Europe and the United States, achieving significant commercial success. In the generic drug sector, Dr. Meng spearheaded the registration and market launch of multiple ANDA products in the U.S., acquiring over 100 U.S. ANDA approvals through self-research and acquisitions. Collaborating with several enterprises in China, he successfully promoted the market entry of generic drugs in the U.S., capturing substantial market share. In the OTC segment, Dr. Meng led his team through nearly a decade of effort to enable Made in China softgel OTC medications to enter mainstream U.S. channels, including Walmart and CVS, positioning the company as a benchmark for internationalization among Chinese pharmaceutical enterprises. As a renowned cGMP expert, Dr. Meng has led and assisted numerous API and formulation companies in China to successfully pass FDA, EMA, and EDQM on-site inspections with outstanding results, helping Chinese pharmaceutical companies expand globally.

E.N.D

Previous article recommendations:

Leading Enterprises Eligible for Up to 100 Million Yuan in Rewards! Guangzhou Nansha Unveils New Policies to Support Gene Therapy, Cell Therapy, and Other Biopharmaceutical Industries

FDA Releases Two Draft Guidelines Related to the Manufacturing Process of Cell and Gene Therapy Drugs

Start-up company Xinghe Désir completes nearly 100 million yuan in angel financing, accelerating the R&D of nucleic acid drugs and their delivery systems

Innovent Biologics Announces the Appointment of Dr. Su-Hua Zhang as Global Chief Business Officer

Nature Reports Westlake University Team’s First Revelation of the Truth About T Cell "Special Forces"

The world's first universal cell therapy product based on iPSC and chemical induction to enter the new drug registration clinical stage in the field of Parkinson's disease treatment has completed the first patient dosing at Zhongnan Hospital of Wuhan University.

Shenzhen Establishes Synthetic Biology Industry Fund with Investment of 1.5 Billion Yuan

Priced at $3.5 Million, Pfizer's AAV Gene Therapy BEQVEZ Approved by FDA for Market Launch

China's First Allogeneic γδ-T Cell Drug Receives Clinical Trial Implied Consent from the National Medical Products Administration

World's First Non-Viral Vector Gene-Modified TIL Therapy Approved for Clinical Use

17 Times in 8 Years, What Did This Gene Therapy Company Do Right?

Ten Fields Worth Noting in China's Biopharmaceutical Industry for the Next Decade (Order Not Ranked)

China's Zhengda Tianqing Completes Phase I Clinical Study of Self-Developed siRNA Innovative Drug TQA3038

The World's First AI-Generated Gene Editor Released

Zonal Ultracentrifugation Breaks Through Process Scaling Limitations, Opens New Avenues for Large-Scale AAV Purification

Academician Zheng Hairong's Team Develops Sonothermal Transfection Technology, Expected to Solve Key Challenges in Cell and Gene Therapy

Analysis and Outlook of the Nucleic Acid Drug Industry

First China-Produced Self-Developed AAV Gene Therapy for Treatment of Primary Parkinson's Disease and AADCD Approved for Clinical Trials

Hengrui Medicine Subsidiary's First Gene Therapy Product Approved for Clinical Trials

Fosun Pharma's CAR-T Product Yikaida® Second-Line Indication Included in Shanghai Huibao

Another CAR-T Commercial Production Base Breaks Ground in China

Heavyweight! "Several Measures of Beijing Municipality to Support the High-Quality Development of Innovative Pharmaceuticals (2024)》Released

Bi Jingquan: Understanding Innovative Drugs from the Perspective of Innovation and Clinical Value

Shanghai Pharmaceuticals Biologics' CAR-iNKT and AXL-CAR T Cell Therapies Debut at the 2024 AACR Conference

Global Renowned Investment Bank: It's Time to Invest in Biotechnology

Statement: The content is sourced fromHaichang Biotech, This article aims at knowledge sharing. All content is for reference only and does not constitute any advice.